{"entity":{"id":"pantum-detect","kind":"drug","name":"PanTum Detect","aka":["EDIM test","EDIM-CS"],"tldr":"A German blood test sold through a private health insurance add-on, which claims to signal cancer of any type; its published evidence is small studies and case reports.","summary":"Zyagnum AG of Darmstadt markets PanTum Detect as tumour-independent (it does not say which organ) and states on its website that it is IVDR-certified under Regulation (EU) 2017/746 with notified body TÜV Rheinland (CE 0197). It is sold through the HanseMerkur Krebs-Scan insurance add-on, reported at about 238 euros a year for a 50-year-old (Pharmazeutische Zeitung, 10 August 2023); that is an insurance premium, not a test price.\n\nThe largest peer-reviewed study found (Saman et al., Cancer Biomarkers 2020) tested 62 patients with bile duct, pancreatic or colorectal cancer against 29 controls: the combined score was positive in all 62 and in none of the healthy controls, and in 7.7% of 13 people with inflammation. Other publications are case reports. Higher sensitivity and specificity figures circulating in news coverage could not be traced to a primary source.","status":"emerging","asOf":"2026-10-29","links":[{"label":"Zyagnum: PanTum Detect","url":"https://www.zyagnum.com/"},{"label":"Saman et al., Cancer Biomarkers 2020","url":"https://doi.org/10.3233/CBM-190414"},{"label":"ClinicalTrials.gov NCT06456216","url":"https://clinicaltrials.gov/study/NCT06456216"},{"label":"ClinicalTrials.gov NCT06842615","url":"https://clinicaltrials.gov/study/NCT06842615"}],"tags":["test","mced","evidence:insufficient"],"related":[],"cancers":[],"sections":[],"technologies":["mced","liquid-biopsy","proteomics"],"targets":[],"drugs":[],"companies":["zyagnum"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Evidence grade insufficient for the claim that taking this test reduces late-stage diagnosis or cancer deaths: no randomised trial of it has reported either outcome, and its published performance comes from case-control or single-arm studies. The only randomised result for any multi-cancer test, NHS-Galleri, did not show fewer stage III or IV cancers.","IVDR certification concerns analytical and clinical performance claims made to a notified body, not proof that screening helps.","What a result means: a positive result is a reason for further tests, not a diagnosis; a negative result does not rule cancer out and does not replace the screening tests that have been shown to work (bowel, breast, cervical and, where eligible, lung screening)."],"brand":"PanTum Detect","modality":"Cancer blood test (Apo10 and TKTL1 epitopes in monocytes, flow cytometry)","mechanism":"Epitope detection in monocytes (EDIM): flow cytometry measures two markers, Apo10 and TKTL1, inside blood monocytes that have taken up tumour material, giving a tumour-independent score.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/pantum-detect/","neighbours":{"technology":[{"id":"liquid-biopsy","kind":"technology","name":"Liquid biopsy (ctDNA)","route":"/technologies/liquid-biopsy/"},{"id":"mced","kind":"technology","name":"Multi-cancer early detection (MCED)","route":"/technologies/mced/"},{"id":"proteomics","kind":"technology","name":"Proteomics & phosphoproteomics","route":"/technologies/proteomics/"}],"company":[{"id":"zyagnum","kind":"company","name":"Zyagnum","route":"/companies/zyagnum/"}],"trial":[{"id":"pantum-detect-max-healthcare","kind":"trial","name":"PanTum Detect diagnostic accuracy study (Max Healthcare, India)","route":"/trials/pantum-detect-max-healthcare/"},{"id":"pantumpet","kind":"trial","name":"PanTumPET (PanTum Detect against PET-CT, Comenius University)","route":"/trials/pantumpet/"}]}}